Astrazeneca Pharma India Ltd. (ASTRAZEN): Astrazeneca Pharma India Share Price near 52-week low: what the latest move means
- September 17, 2026
- Posted by: Harsh Piplani
- Category: News
Astrazeneca Pharma India Share Price opened, traded and closed with little change on 17 September 2026, leaving Astrazeneca Pharma India Ltd. (ASTRAZEN) close to its 52-week low. The stock was last seen at Rs 6,707.45, down Rs 3.35 or 0.05%, with market capitalisation of Rs 16,777 crore. This Astrazeneca Pharma India Share Price update matters because the session kept the stock in the yearly-low zone even though the move was small. The supplied data confirms the price event but does not establish a company-specific catalyst, so the focus stays on the measurable market response, valuation backdrop and sector positioning that are driving Astrazeneca Pharma India Stock News and Astrazeneca Pharma India Share Price Today searches.
For investors tracking Astrazeneca Pharma India Share Price live, the key question is not only why the stock is under pressure, but also whether the current price action and premium valuation can coexist with the company’s earnings quality. Univest’s AI research note looks at the stock from a market, technical, fundamental and sector lens, using only verified data.
Astrazeneca Pharma India Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 6,707.45 |
| Previous Close | Rs 6,710.8 |
| Today's Move | Rs -3.35 (-0.05%) |
| Open | Rs 6,710.8 |
| High | Rs 6,719.9 |
| Low | Rs 6,680 |
| Turnover | Rs 0.06 crore |
| Market Capitalisation | Rs 16,777 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,707.45 versus the previous close of Rs 6,710.8, a fall of 0.05%. The stock opened at Rs 6,710.8, reached a high of Rs 6,719.9, touched a low of Rs 6,680.
Astrazeneca Pharma India Share Price Today shows a narrow session: the stock opened at Rs 6,710.80, matched the previous close at Rs 6,710.80, touched an intraday high of Rs 6,719.90 and a low of Rs 6,680. The day ended at Rs 6,707.45, leaving a decline of Rs 3.35 or 0.05%. Turnover stood at Rs 0.06 crore, while market capitalisation remained Rs 16,777 crore. This is a low-volatility session in absolute price terms, but it still keeps Astrazeneca Pharma India Share Price near its 52-week low and in the wider discussion of Stocks in News, Top Losers Today and Stocks at 52 Week Low.
The price action indicates that selling pressure was present, even if the move was modest. Because the stock is trading close to a one-year low, the current Astrazeneca Pharma India Share Price structure is drawing attention from traders who monitor support levels and Price Action closely. The session confirms why Astrazeneca Pharma India Share Price News is being searched alongside Astrazeneca Pharma India Stock Performance and Astrazeneca Pharma India Share Price Update.
Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 16,777 crore |
| P/E Ratio | 98.91x |
| P/B Ratio | 18.55x |
| ROE | 23.02% |
| ROCE | 31.24% |
| EPS | Rs 67.85 |
| Book Value Per Share | Rs 361.68 |
| Dividend Yield | 0.54% |
Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 98.91x, P/B 18.55x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.
Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 16777 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 98.91x, P/B at 18.55x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.54%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 28.1x, median ROE of 11.7%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 98.91x |
| Benchmark Median P/E | 28.1x |
| Benchmark Average P/E | 40.11x |
| Benchmark P/E Range | 0x to 661.74x |
| Company P/B Ratio | 18.55x |
| Benchmark Median P/B | 2.92x |
| Company ROE | 23.02% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 31.24% |
| Benchmark Median ROCE | 13.61% |
| Company Market Capitalisation | Rs 16,777 crore |
| Benchmark Median Market Cap | Rs 730.86 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 98.91x, which is above the benchmark median of 28.1x, a difference of +251.99%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.7%, a difference of +96.75%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.61%, a difference of +129.54%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Glenmark Life Sciences Ltd. | ALIVUS | 16,837.49 | 27.92 | 4.83 | 18.41 | 24.61 |
| Suven Pharmaceuticals Ltd. | COHANCE | 16,206.82 | 156.04 | 4.31 | 4.02 | 6.12 |
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,193.85 | 23.37 | 2.77 | 12.35 | 11.74 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 16,081.02 | 45.36 | 2.24 | 5.97 | 8.69 |
| Shilpa Medicare Ltd. | SHILPAMED | 17,834.13 | 61.02 | 6.75 | 9.82 | 11.43 |
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 98.91x compared with the displayed peer median of 45.36x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 9.82% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 11.43%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 16,777 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Astrazeneca Pharma India
- Astrazeneca Pharma India Share Price is near its 52-week low, keeping the stock in focus for Share Market Today screens.
- The session was flat-to-weak, with price action showing only a small decline but continued proximity to the yearly low.
- Astrazeneca Pharma India Fundamental Analysis shows strong ROE, ROCE and EPS, but a premium P/E and P/B.
- The healthcare sector benchmark suggests the stock trades at a much higher valuation than the same-industry median.
- Peer Comparison shows better profitability than several listed peers, which keeps Astrazeneca Pharma India Stock News relevant.
About Astrazeneca Pharma India
Astrazeneca Pharma India Ltd. operates in Pharmaceuticals & Drugs within the Healthcare sector. The business profile places it among established listed pharma names tracked on NSE and BSE, with a market capitalisation of Rs 16,777 crore. Based on the supplied financial data, the company has delivered revenue growth across the recent quarters, with turnover rising to Rs 6,827.9 crore in Jun 2026 from Rs 5,263.1 crore in Jun 2025. Profit has been more variable, which is visible in the quarterly net profit series.
For investors studying Astrazeneca Pharma India Share Price Today, the company’s profile matters because it combines premium valuation with solid profitability ratios. The supplied data also shows EPS of Rs 67.85 and book value of Rs 361.68, which help frame Astrazeneca Pharma India Share Price in a broader financial context. This makes the stock a frequent name in Astrazeneca Pharma India Latest News and Astrazeneca Pharma India Company News coverage.
Track Astrazeneca Pharma India Share Price on Univest
Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Investors can track Astrazeneca Pharma India Share Price on Univest for live price updates, technical indicators, fundamental ratios, shareholding pattern, 52-week levels and market insights. Univest combines stock analysis, sector context and peer comparison in one place so readers can follow Astrazeneca Pharma India Share Price Today, Astrazeneca Pharma India Stock News and Astrazeneca Pharma India Share Price Live without switching between multiple dashboards.
The platform also helps users monitor Astrazeneca Pharma India Stock Performance, Astrazeneca Pharma India Latest News and Astrazeneca Pharma India Share News alongside broader healthcare market updates. For a stock trading near a 52-week low, that combined view can be useful for keeping the price action, valuation and company context in one editorial flow.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Astrazeneca Pharma India Share Price near a 52-week low?
Ans. The latest session kept Astrazeneca Pharma India Share Price close to its 52-week low after a small decline. The data confirms the price event, but it does not establish a company-specific catalyst for the move.
What is Astrazeneca Pharma India Share Price today?
Ans. Astrazeneca Pharma India Share Price was Rs 6,707.45, down Rs 3.35 or 0.05% on the session. The stock opened at Rs 6,710.80 and ended very close to the previous close.
What does Astrazeneca Pharma India Share Price say about market sentiment?
Ans. The price action suggests cautious sentiment. The move was small, but the stock stayed near its yearly low, which keeps Astrazeneca Pharma India Share Price in focus for traders watching support and selling pressure.
Is Astrazeneca Pharma India Share Price expensive?
Ans. On the supplied numbers, Astrazeneca Pharma India Share Price trades at a P/E of 98.91 and P/B of 18.55. Those multiples are well above the same-industry benchmark median and average.
How strong are Astrazeneca Pharma India fundamentals?
Ans. Astrazeneca Pharma India Fundamental Analysis shows ROE of 23.02%, ROCE of 31.24%, EPS of Rs 67.85 and book value of Rs 361.68. These figures indicate strong profitability relative to peers.
What does the sector comparison show for Astrazeneca Pharma India Share Price?
Ans. The company’s P/E, P/B, ROE and ROCE all stand above the same-industry median or average. That makes Astrazeneca Pharma India Share Price a premium-valued pharma name in the healthcare universe.
How does Astrazeneca Pharma India compare with peers?
Ans. Astrazeneca Pharma India Share Price carries richer valuation multiples than Glenmark Life Sciences, Alembic Pharmaceuticals, Jubilant Pharmova, Shilpa Medicare and Eris Lifesciences, while showing stronger ROE and ROCE than most of them.
What is the market capitalisation of Astrazeneca Pharma India?
Ans. Astrazeneca Pharma India Share Price corresponds to a market capitalisation of Rs 16,777 crore. That places the company above the same-industry median and close to the peer cluster provided in the dataset.
What should investors monitor next in Astrazeneca Pharma India Share Price?
Ans. Investors may monitor price action around the yearly low, quarterly revenue and profit trends, and the valuation gap versus sector benchmarks. Univest tracks these elements together for a fuller stock view.
Can Astrazeneca Pharma India Share Price be tracked on Univest?
Ans. Yes. Univest provides Astrazeneca Pharma India Share Price updates alongside live price, key ratios, shareholding pattern, 52-week levels and sector context, helping readers follow the stock in one place. The stock moved -0.05% during the session.
